Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.HemCon Medical Technologies has announced it will use Germany-based SanguiBioTech's ChitoSkin technology platform to help further innovations in hemostatic bandages and wound care dressings for the acute care market.
Subscribe to our email newsletter
Under the terms of the agreement, HemCon will leverage Sangui’s technology platform to enhance and expand its product offerings for surgical and wound care. HemCon developed the chitosan-based hemostatic HemCon Bandages and ChitoFlex dressings that are used by military and medical first responders as well as health care professionals around the globe.
HemCon retains exclusive worldwide market and distributing rights for products developed under this structured financial agreement. HemCon will submit developed products for US approvals to the FDA, while Sangui will prepare documentation for registration in the EU.
John Morgan, president and CEO of HemCon, said: “We explored a wide variety of technology platforms to add to our new surgical and wound care offerings and feel that the Sangui chitosan platform offers great opportunities to enhance our solutions.”